A Dose Finding Study Of A New Medication, PF-00337210 That Will Possibly Decrease Blood Supply To Tumors

Phase I, Open-Label, Multi-Center, Accelerated Dose Escalation Study Of The Anti-Angiogenesis Agent PF-00337210 In Patients With Advanced Solid Tumors

This study will test a new cancer medication to determine if this medication will block blood supply to a tumor and decrease growth of a tumor. This study will also define the safety profile and define the safest dose of this new medication for people who have cancer.

Inclusion Criteria:

• Histologically or cytologically confirmed advanced solid tumors un-responsive to currently available therapies or for which there is no standard therapy.
• At least 1 measurable disease site as defined by Response Evaluation Criterion in Solid Tumors [RECIST].
• Adequate bone marrow, liver function and renal function as defined by protocol.
• Blood pressure Requirements During dose escalation - no evidence of pre-existing hypertension and no antihypertensive medications at baseline.

During dose expansion - patient's whose hypertension is controlled by antihypertensive therapy.

Exclusion Criteria:

• Chemotherapy, radiotherapy or any investigational therapy within 4 weeks of study entry
• Current use or anticipated need for drugs that are known CYP34 inhibitors or inducers.
• Patients with carcinomatous meningitis or un-treated brain metastases.
• Any acute cardiovascular incident within the past 12 months.
• Patients with active gastrointestinal bleeding or significant gastrointestinal abnormalities as defined by protocol
• Patients with no evidence of the following for 5 years: malignancy or metastatic disease of skin cancer (except melanoma), in situ cervical cancer or breast cancer or T1C prostate cancer.